Pacific Biosciences of California, Inc.
(NASDAQ GS: PACB)
Attention investors who purchased shares of Pacific Biosciences of California, Inc. before November 1, 2018:
Rigrodsky & Long is investigating potential claims against the board of directors of Pacific Biosciences of California, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Illumina, Inc. for $8.00 per share, or approximately $1.2 billion.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Pacific Biosciences of California, Inc. (“Pacific Biosciences” or the “Company”) (NASDAQ GS: PACB) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Illumina, Inc. (“Illumina”) (NASDAQ GS: ILMN) in a transaction valued at approximately $1.2 billion. Under the terms of the agreement, shareholders of Pacific Biosciences will receive $8.00 in cash for each share of Pacific Biosciences common stock.
If you own common stock of Pacific Biosciences and purchased any shares before November 1, 2018, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at email@example.com, or at https://www.rigrodskylong.com/offices-contact.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.